![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Biogen’s Neuroreparative Candidate for MS Flounders in Phase 2 Study
Biogen’s Neuroreparative Candidate for MS Flounders in Phase 2 Study
Biogen’s multiple sclerosis candidate opicinumab missed primary endpoints in a Phase 2 study for multiple sclerosis.
Dubbed Anti-LINGO-1, the candidate did not meet a multicomponent endpoint of improvement of ambulation, upper extremity function, cognition and physical disability at three months in 418 participants with relapsing forms of multiple sclerosis.
The neuroreparative therapy also missed a second endpoint that measured the slowing of progression for those components. Biogen plans to analyze the data to inform the design of future studies for the therapy.
Upcoming Events
-
21Oct